Real-time Estimate
Cboe BZX
02:23:16 2024-05-15 pm EDT
|
5-day change
|
1st Jan Change
|
3.12
USD
|
-0.95%
|
|
+1.30%
|
-6.33%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
866.6
|
302.5
|
198.7
|
261
|
-
|
-
|
Enterprise Value (EV)
1 |
653.7
|
228.5
|
198.7
|
261
|
261
|
261
|
P/E ratio
|
-5.36
x
|
-2.26
x
|
-1.44
x
|
-1.68
x
|
-1.77
x
|
-1.66
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
58.2
x
|
88.9
x
|
145
x
|
13.2
x
|
12.5
x
|
EV / Revenue
|
-
|
58.2
x
|
88.9
x
|
145
x
|
13.2
x
|
12.5
x
|
EV / EBITDA
|
-9,509,103
x
|
-2,412,755
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-6,468,606
x
|
-18,278,022
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
1.3
x
|
0.98
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
54,641
|
58,974
|
59,835
|
82,847
|
-
|
-
|
Reference price
2 |
15.86
|
5.130
|
3.320
|
3.150
|
3.150
|
3.150
|
Announcement Date
|
3/17/22
|
3/16/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
5.199
|
2.235
|
1.802
|
19.78
|
20.86
|
EBITDA
|
-91.14
|
-125.4
|
-
|
-
|
-
|
-
|
EBIT
1 |
-94.88
|
-133.8
|
-146.5
|
-139.9
|
-147.4
|
-205
|
Operating Margin
|
-
|
-2,574.17%
|
-6,556.87%
|
-7,763.08%
|
-745.39%
|
-982.51%
|
Earnings before Tax (EBT)
1 |
-95.78
|
-130.8
|
-134.8
|
-129.7
|
-143.6
|
-205
|
Net income
1 |
-95.82
|
-130.9
|
-136.7
|
-133.3
|
-135.6
|
-165.4
|
Net margin
|
-
|
-2,518.41%
|
-6,115.12%
|
-7,398.05%
|
-685.47%
|
-792.91%
|
EPS
2 |
-2.960
|
-2.270
|
-2.300
|
-1.880
|
-1.777
|
-1.895
|
Free Cash Flow
|
-134
|
-16.55
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-318.37%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/22
|
3/16/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
1.058
|
1.396
|
2.224
|
0.521
|
1.72
|
0.099
|
0.148
|
0.268
|
0.855
|
0.3667
|
0.3667
|
0.3667
|
0.55
|
0.55
|
EBITDA
|
-26.92
|
-
|
-
|
-
|
-
|
-
|
-27.62
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-27.97
|
-27.44
|
-31.35
|
-31.74
|
-33.31
|
-32.08
|
-30.86
|
-35.63
|
-43.76
|
-31.31
|
-34
|
-36.28
|
-38.28
|
-39.2
|
-41.45
|
Operating Margin
|
-
|
-2,593.19%
|
-2,245.77%
|
-1,427.07%
|
-6,392.71%
|
-1,865.17%
|
-31,168.69%
|
-24,071.62%
|
-16,329.1%
|
-3,661.87%
|
-9,272.64%
|
-9,893.09%
|
-10,438.54%
|
-7,127.27%
|
-7,536.36%
|
Earnings before Tax (EBT)
1 |
-28.87
|
-37.5
|
-30.97
|
-30.72
|
-31.65
|
-30.06
|
-32.34
|
-32.13
|
-40.27
|
-28.06
|
-31.69
|
-33.92
|
-36.15
|
-37.29
|
-39.88
|
Net income
1 |
-28.19
|
-37.51
|
-30.99
|
-30.75
|
-31.68
|
-31.26
|
-33.29
|
-32.72
|
-39.4
|
-28.06
|
-31.69
|
-33.92
|
-36.15
|
-37.29
|
-39.88
|
Net margin
|
-
|
-3,545.65%
|
-2,219.77%
|
-1,382.6%
|
-6,081%
|
-1,817.67%
|
-33,627.27%
|
-22,108.11%
|
-14,700.75%
|
-3,282.11%
|
-8,641.97%
|
-9,250.48%
|
-9,859%
|
-6,779.55%
|
-7,250%
|
EPS
2 |
-0.2400
|
-0.6600
|
-0.5400
|
-0.5300
|
-0.5500
|
-0.5300
|
-0.5600
|
-0.5500
|
-0.6600
|
-0.4500
|
-0.4700
|
-0.4840
|
-0.5000
|
-0.5300
|
-0.5233
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/22
|
5/16/22
|
8/11/22
|
11/10/22
|
3/16/23
|
5/11/23
|
8/9/23
|
11/9/23
|
3/14/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
213
|
74
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-134
|
-16.6
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-66.1%
|
-37.5%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-35.2%
|
-28.3%
|
-
|
-
|
-
|
-
|
Assets
1 |
272.1
|
462
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
12.20
|
5.240
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-2.750
|
0.2400
|
-
|
-
|
-
|
-
|
Capex
|
45
|
30.6
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
588.65%
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/22
|
3/16/23
|
3/14/24
|
-
|
-
|
-
|
Last Close Price
3.15
USD Average target price
14.17
USD Spread / Average Target +349.74% Consensus |
1st Jan change
|
Capi.
|
---|
| -5.12% | 261M | | +29.03% | 49.18B | | -0.10% | 42.11B | | +48.26% | 40.37B | | -5.26% | 28.85B | | +11.48% | 26.09B | | -22.74% | 18.71B | | +9.06% | 13.26B | | +30.01% | 12.32B | | -1.51% | 11.99B |
Other Biotechnology & Medical Research
|